Poland· PL-100000623
Arthryl Fast
A glucosamine product containing glucosamini sulfas + lidocaini hydrochloridum, registered in Poland by Cooper Consumer Health B.V.. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Glucosamine is registered in 14 of 19 countries.
Countries holding a registration under ATC M01AX05 (glucosamine), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Glucosamine · ATC M01AX05
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- United Kingdom
Price per daily dose
What a daily dose of glucosamine costs, country by country.
Normalised to the WHO defined daily dose (1.5 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Glucosamine · price per daily dose (1.5 g)
USD · FX 28 Sept 2026
- ES Spain$0.23
The record
At a glance
URPL (Poland)- Active substance
- Glucosamini sulfas + Lidocaini hydrochloridum
- Manufacturer
- Cooper Consumer Health B.V.
- Country
- Poland (PL)
- ATC code
- M01AX05
- ATC class
- Glucosamine
- Defined daily dose
- 1.5 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991029944
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for glucosamine.
Graded by severity as the source publishes them — 2 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Glucosamine · interactions on record
2 records
- 2 moderate
Most severe, free to view
- DicoumarolB01AA01moderate
- WarfarinB01AA03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under M01AX05
Glucosamine, as other registers publish it.
- United KingdomAlateris 625mg tabletsLexon (UK) Ltd
- United KingdomAlateris 625mg tabletsWaymade Healthcare Plc
- United KingdomAlateris 625mg tabletsMWK Healthcare Ltd
- CzechiaARTAXINLaboratorio Reig Jofré S.A., Barcelona
- CzechiaARTAXINLaboratorio Reig Jofré S.A., Barcelona
- CzechiaARTAXINLaboratorio Reig Jofré S.A., Barcelona
- FinlandArthrimelSTADA Arzneimittel AG
- IrelandArthrimel 1500mg Film Coated TabletsPhoenix Labs
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cfe62184-d44c-4e67-990a-98450a6b7ea4 GET /v1/drugs/cfe62184-d44c-4e67-990a-98450a6b7ea4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "(400 mg + 10 mg)/2 ml",
"packaging": "05909991029944 ¦ Rp ¦ 59236\n6 amp. 2 ml ¦ 6 amp. 1 ml",
"substance": "Glucosamini sulfas 400 mg/2 ml + Lidocaini hydrochloridum 10 mg/2 ml",
"common_name": "Glucosamini sulfas + Lidocaini hydrochloridum",
"pl_product_id": "100000623",
"pozwolenie_nr": "20761",
"auth_procedure": "NAR",
"authorisation_validity": "Bezterminowe"
}See everything about glucosamine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.